Highly rated in
Highly rated in
Check Dr. Christine Lu-Emerson's experience treating your condition:
About Dr. Christine Lu-Emerson

Christine Lu-Emerson is a Neurologist in South Portland, Maine. Lu-Emerson has been practicing medicine for over 17 years and is highly rated in 21 conditions, according to our data. Her top areas of expertise are Glioblastoma, Glioma, Astrocytoma, and Brain Tumor. She is licensed to treat patients in Maine and Washington. Lu-Emerson is currently accepting new patients.

Her clinical research consists of co-authoring 7 peer reviewed articles and participating in 7 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Christine Lu-Emerson it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Christine Lu-Emerson accepts the following insurance:

  •  Ambetter
  •  Anthem

Call to see if your plan is accepted.
265 Western Ave, Suite 2, South Portland, ME 04106
Other Locations
100 Campus Dr, Suite 121, Scarborough, ME 04074
Background & Education
Graduate Institution
New York University School Of Medicine, 2005
Psychiatry & Neurology in WA
Hospital Affiliations
York Hospital
LincolnHealth - Miles Campus And Hospital
MaineGeneral Medical Center - Alfond Center For Health
Mid Coast Hospital
Memorial Hospital
Northern Light Mercy Hospital - State Street Campus
Maine Medical Center
Pen Bay Medical Center
St Marys Health System
New England Rehabilitation Hospital Of Portland
Southern Maine Health Care - Biddeford
Stephens Memorial Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
View 3 Less Clinical Trials -

7 Total Publications

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors